PURPOSE: CD163, a scavenger receptor for haptoglobin-hemoglobin complexes, is almost exclusively expressed by monocytes and macrophages and is shedded (as sCD163) by inflammatory stimuli. Thus, high serum levels of sCD163 predicted mortality in certain inflammatory diseases. We investigated baseline levels, time course of sCD163 levels and CD163 gene expression in relation to mortality and clinical complications in a large heterogeneous cohort of critically ill patients. METHODS: In this pre-planned secondary analysis of two randomized clinical studies, critically ill patients (n = 1657) were randomized to "conventional" (insulin administered only for blood glucose levels above 215 mg/dL) or "intensive" insulin therapy (glycemia maintained at 80-110 mg/dL) and compared with healthy controls (n = 112). RESULTS: Upon admission, critically ill patients had 1.6-fold higher sCD163 levels than controls (P < 0.0001). Long-stay patients (ICU stay >5 days), non-survivors and patients who developed liver dysfunction or kidney injury had higher baseline sCD163 levels. In multivariable analyses, elevated baseline sCD163 levels were independently associated with ICU mortality, liver dysfunction, and time to discharge from ICU and hospital. sCD163 further increased during ICU stay in patients who developed organ dysfunction and in non-survivors. Avoiding hyperglycemia with insulin slightly reduced circulating sCD163 levels. Hepatic CD163 gene expression in patients was higher than in controls (P = 0.002) and correlated positively with sCD163 levels (P = 0.345, P < 0.0001). CONCLUSIONS: This study hallmarks the association of elevated sCD163 with organ dysfunction and adverse outcome of critical illness and may point to the liver as a potential source.
RCT Entities:
PURPOSE:CD163, a scavenger receptor for haptoglobin-hemoglobin complexes, is almost exclusively expressed by monocytes and macrophages and is shedded (as sCD163) by inflammatory stimuli. Thus, high serum levels of sCD163 predicted mortality in certain inflammatory diseases. We investigated baseline levels, time course of sCD163 levels and CD163 gene expression in relation to mortality and clinical complications in a large heterogeneous cohort of critically illpatients. METHODS: In this pre-planned secondary analysis of two randomized clinical studies, critically illpatients (n = 1657) were randomized to "conventional" (insulin administered only for blood glucose levels above 215 mg/dL) or "intensive" insulin therapy (glycemia maintained at 80-110 mg/dL) and compared with healthy controls (n = 112). RESULTS: Upon admission, critically illpatients had 1.6-fold higher sCD163 levels than controls (P < 0.0001). Long-stay patients (ICU stay >5 days), non-survivors and patients who developed liver dysfunction or kidney injury had higher baseline sCD163 levels. In multivariable analyses, elevated baseline sCD163 levels were independently associated with ICU mortality, liver dysfunction, and time to discharge from ICU and hospital. sCD163 further increased during ICU stay in patients who developed organ dysfunction and in non-survivors. Avoiding hyperglycemia with insulin slightly reduced circulating sCD163 levels. Hepatic CD163 gene expression in patients was higher than in controls (P = 0.002) and correlated positively with sCD163 levels (P = 0.345, P < 0.0001). CONCLUSIONS: This study hallmarks the association of elevated sCD163 with organ dysfunction and adverse outcome of critical illness and may point to the liver as a potential source.
Authors: Katharine A Hintz; Athos J Rassias; Kathleen Wardwell; Marcia L Moss; Peter M Morganelli; Patricia A Pioli; Alice L Givan; Paul K Wallace; Mark P Yeager; Paul M Guyre Journal: J Leukoc Biol Date: 2002-10 Impact factor: 4.962
Authors: Lucia A Possamai; Charalambos Gustav Antoniades; Quentin M Anstee; Alberto Quaglia; Diego Vergani; Mark Thursz; Julia Wendon Journal: World J Gastroenterol Date: 2010-04-21 Impact factor: 5.742
Authors: Dominique Baeten; Pieter Demetter; Claude A Cuvelier; Elli Kruithof; Nancy Van Damme; Martine De Vos; Eric M Veys; Filip De Keyser Journal: J Pathol Date: 2002-03 Impact factor: 7.996
Authors: Jonas Axelsson; Holger Jon Møller; Anna Witasp; Abdul Rashid Qureshi; Juan Jesus Carrero; Olof Heimbürger; Peter Bárány; Anders Alvestrand; Bengt Lindholm; Søren K Moestrup; Peter Stenvinkel Journal: Am J Kidney Dis Date: 2006-12 Impact factor: 8.860
Authors: Michael Reid; Yifei Ma; Rebecca Scherzer; Jennifer C Price; Audrey L French; Michael W Plankey; Carl Grunfeld; Phyllis C Tien Journal: AIDS Date: 2017-01-28 Impact factor: 4.177
Authors: Anders G Kjærgaard; Sidsel Rødgaard-Hansen; Anders Dige; Jan Krog; Holger J Møller; Else Tønnesen Journal: PLoS One Date: 2014-03-17 Impact factor: 3.240
Authors: Saleh A Al-Quraishy; Mohamed A Dkhil; Abdel-Azeem A Abdel-Baki; Denis Delic; Frank Wunderlich Journal: Front Microbiol Date: 2016-07-14 Impact factor: 5.640
Authors: Timothy K O'Malley; Tricia H Burdo; Jake A Robinson; Kathleen V Fitch; Steven K Grinspoon; Suman Srinivasa Journal: AIDS Date: 2017-07-31 Impact factor: 4.632